

FACT SHEET

- ◆ The T.J. Martell Foundation for Cancer Research was founded in 1975 when music industry executive Tony Martell promised his son, T.J., a young victim of leukemia, he would raise a million dollars to fight the disease. In 44 years, the Foundation has provided over \$280 million for research at nine flagship hospitals in the United States.
- ◆ Through the T.J. Martell Foundation's venture capital, many of our supported scientific researchers have been able to leverage our funding through sources such as the National Institutes of Health and the National Cancer Institute with the mission of developing clinical trials and new drug discoveries. We can conservatively estimate that our funding has resulted in approximately \$1 billion in additional research funding.
- ◆ We support research at nine top hospitals in the United States. Current research facilities funded by the Foundation include:
 - Mount Sinai Medical Center
 - Columbia-Presbyterian Cancer Center
 - Children's Hospital Los Angeles
 - University of Texas MD Anderson Cancer Center
 - University of California San Francisco
 - Memorial Sloan-Kettering Cancer Center
 - Vanderbilt-Ingram Cancer Center
 - Winship Cancer Institute at Emory University
 - City of Hope
- ◆ The essence of Martell funding includes four central operational core principles:
 - First and foremost, great science improving and progressing year on year
 - Nurturing the next generation of basic, translational and clinical scientists
 - Supporting high-risk, high-gain research wherein seed funding can establish proof-of-concept to compete for larger NIH grants
 - Encouraging collaborations between the funded centers
- ◆ Research Breakthroughs include:
 - Neuroblastoma, a deadly form of cancer attacking young children, had a survival rate of less than 20%. For over 30 years, the T.J. Martell Foundation has supported research in this field and now the cure rate is 45%. We continue to fund this effort with the expectation that we will soon have a 100% cure rate.
 - The T.J. Martell Foundation supported researchers at Columbia-Presbyterian Medical Center isolated the "killer" prostate cancer gene (oncogene). Work has begun on developing targeted therapy to block or turn-off this prostate oncogene.
 - Neuropsychology investigators funded by the T.J. Martell Foundation at Memorial Sloan Kettering have discovered the gene that predisposes breast cancer patients to develop "chemo brain" and have begun to develop a better understanding of the brain changes that occur and interventions to enhance attention and memory in patients on chemotherapy. Our Psychotherapy researchers have developed novel, effective counseling interventions to reduce fear of recurrence in breast cancer patients, and reduce distress in cancer caregivers.

- Lung cancer investigators funded by the T.J. Martell Foundation at MD Anderson Cancer Center have discovered for the first time that the immune cell populations in different regions within the same tumors are different, a phenomena termed as immune intra-tumor heterogeneity and the extent of immune intra-tumor heterogeneity is associated with risks of lung cancer recurrence after surgery, therefore, suggested different treatment strategy is needed for different patients.
- The Foundation supports the Physician Scientist Program at the University of Texas MD Anderson Cancer Center. M.D. Anderson's Physician-Scientist Program launches the career of the best and brightest young faculty members who receive up to five years of research support with 80% dedicated research time and intensive mentoring to attain independent federal grant support. Graduates of the program are established, independent researchers, who are well prepared to become the leaders of translational cancer research, nationally and internationally

• Please visit us at www.tjmartell.org

Updated 2.11.19